communication with share holders please

The amount of communication from the board is like like watching paint dry they need to keep us in the know even if they are worthless announcements at least we have something to talk about ...

Maybe Im going over old ground here , however if you have missed the announcement from Tacere here below .

all good things come to those's who wait maybe 3-5 years they have poor communication with share holders and need a PR man to build awareness to this future multi billion dollar company.

http://www.benitec.com/documents/vanleeuwenhoeck-benitecreport.pdf

Partnerships
Tacere (Pfizer)
In 2006, Benitec made a RNAi licence deal with US company Tacere. As part of this deal Benitec secured upfront payments, milestone payments for using the ddRNAi technology in treating Hepatitis C as well as a 5% equity stake in Tacere. Tacere Therapeutics, Inc. specialises in the development of novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). Combining expertise in RNA interference (RNAi), gene medicine, and novel biologicals, Tacere possesses proprietary skills in the identification and development of RNAi therapeutics. In 2008, Tacere struck a USD 145 million deal with Pfizer to develop and commercialize its HCV compound TT-033, using Benitec’s ddRNAi technology. Upon commercialization of TT-033 Tacere would be entitled to receive royalties on net sales by Pfizer.

http://www.tacerebio.com/pdf_files/Tacere_Oncolys_License_Press_Release-031208.pdf
NEWS
ONCOLYS BIOPHARMA AND TACERE THERAPEUTICS SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE RNAi HEPATITIS C DRUG

Tokyo, Japan and San Jose, California, USA—March 12, 2008 /PR Newswire/ —
Oncolys BioPharma, Inc. (Tokyo, Japan) and Tacere Therapeutics, Inc. (San Jose, CA, USA) announced today that they have entered into a strategic alliance and license agreement to develop and commercialize throughout Asia, Tacere’s RNA interference (RNAi)-based Hepatitis C virus (HCV) compound, TT-033, code-named by Oncolys as OBP-701. This agreement resulted from the strategic alliance entered into by Tacere and Oncolys in June 2007, whereby Oncolys was granted an option to acquire the Asian rights for TT-033.

“We are very pleased to be taking our relationship with Oncolys to the next level. After partnering TT-033 with Pfizer outside of Asia in December 2007, this agreement gives global scope to the development of TT-033/OBP-701 as a first-in-class treatment option for HCV patients,” said Sara M. Hall, Chief Executive Officer of Tacere.

“We are extremely excited about solidifying this historic agreement with Tacere,” said Yasuo Urata, President and Chief Executive Officer of Oncolys. “We recognized the power of this new approach to treating HCV and are delighted to see that the pharmaceutical industry has validated our investment in Tacere and this drug. More than ever, we believe that TT- 033/OBP-701 will enable us to offer new treatments for patients suffering from HCV.”

Under the terms of the agreement, Oncolys and Tacere will form a joint steering committee that will work with the Tacere and Pfizer steering committee to oversee preclinical research and development efforts for TT-033/OBP-701.

In addition to an up-front payment, Tacere will be eligible to receive milestone payments through successful achievement of development, approval, and commercialization milestones resulting in total potential payments to Tacere of up to $60 million. Upon commercialization of TT-033/OBP-701, Tacere would be entitled to receive royalties on net sales by Oncolys. Further, if Oncolys sublicenses its rights under the strategic alliance to any major pharmaceutical company, the milestone payments and sales royalties Oncolys receives will be shared with Tacere at predetermined rates based upon the stage of development at which the milestones occur.